SLC5A2 and chronic kidney disease: Additionally, dapagliflozin, sodium-glucose co-transporter-2 (SGLT-2) inhibitor, has been proven to provide renal and cardiovascular benefits for patients with type 2 diabetes and CKD (7–9).